Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Related news and resources
The innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines
IFPMA introduces the “Innovation Development and Access Pathway” (IDAP), a framework designed to build a shared understanding of the end-to-end pathway of how medicines and vaccines move from discovery to delivery at the point of care. The paper maps the four critical pillars of this journey: R&D and the innovation ecosystem; regulatory processes and life cycle management; listing, procurement and reimbursement; and health service delivery. It identifies systemic challenges, and proposes collaborative solutions to overcome them, and shows that improving access requires coordinated action across stakeholders, with governments playing a central role in enabling timely and equitable access to innovation.
Read more
75th WHO Regional Committee for Europe on the Action Plan for the Prevention and Control of Noncommunicable Diseases in the WHO European Region 2016–2025
On 30 October 2025 at the 75th WHO Regional Committee for Europe, IFPMA, together with European member association EFPIA, submitted a statement on the Action Plan for the Prevention and Control of Noncommunicable Diseases in the WHO European Region 2016-2025. This statement is delivered on behalf of IFPMA and its European member organization EFPIA. We...
Read morePolicy considerations for the development, regulation and adoption of biosimilars
Biosimilars can play a role in expanding patient access to biological medicines and in supporting the sustainability of healthcare systems. To fully realize this potential, IFPMA recommends the adoption of a series of policy recommendations.
Read more